Alnylam Pharmaceuticals Stock Filter Stocks by Fundamentals
| ALNY Stock | USD 145.79 1.38 0.96% |
Alnylam Pharmaceuticals fundamentals help investors to digest information that contributes to Alnylam Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Alnylam Stock. The fundamental analysis module provides a way to measure Alnylam Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Alnylam Pharmaceuticals stock.
Price To Book Ratio is likely to rise to -102.94 in 2024. Alnylam | Price to Book |
Did you try this?
Run Portfolio Anywhere Now
Portfolio AnywhereTrack or share privately all of your investments from the convenience of any device |
| All Next | Launch Module |
Alnylam Fundamentals
| Return On Equity | -15.01 | ||||
| Return On Asset | -0.0478 | ||||
| Profit Margin | (0.24) % | ||||
| Operating Margin | (0.26) % | ||||
| Current Valuation | 18.43 B | ||||
| Shares Outstanding | 126.45 M | ||||
| Shares Owned By Insiders | 0.41 % | ||||
| Shares Owned By Institutions | 95.02 % | ||||
| Number Of Shares Shorted | 2.8 M | ||||
| Price To Earning | (22.92) X | ||||
| Price To Book | 142.92 X | ||||
| Price To Sales | 10.27 X | ||||
| Revenue | 1.83 B | ||||
| Gross Profit | 868.6 M | ||||
| EBITDA | (228.12 M) | ||||
| Net Income | (440.24 M) | ||||
| Cash And Equivalents | 2.27 B | ||||
| Cash Per Share | 18.41 X | ||||
| Total Debt | 2.68 B | ||||
| Debt To Equity | 5.63 % | ||||
| Current Ratio | 3.48 X | ||||
| Book Value Per Share | (1.75) X | ||||
| Cash Flow From Operations | 104.16 M | ||||
| Short Ratio | 3.86 X | ||||
| Earnings Per Share | (3.52) X | ||||
| Price To Earnings To Growth | (0.49) X | ||||
| Target Price | 222.41 | ||||
| Number Of Employees | 2.1 K | ||||
| Beta | 0.4 | ||||
| Market Capitalization | 18.26 B | ||||
| Total Asset | 3.83 B | ||||
| Retained Earnings | (7.01 B) | ||||
| Working Capital | 2.01 B | ||||
| Current Asset | 1.11 B | ||||
| Current Liabilities | 62.1 M | ||||
| Net Asset | 3.83 B |
About Alnylam Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Alnylam Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Alnylam Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Alnylam Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Alnylam Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Alnylam Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Alnylam Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving together with Alnylam Stock
| 0.74 | EVO | Evotec SE ADR Earnings Call Tomorrow | PairCorr |
Moving against Alnylam Stock
| 0.88 | CNTA | Centessa Pharmaceuticals Downward Rally | PairCorr |
| 0.87 | PBH | Prestige Brand Holdings Financial Report 2nd of May 2024 | PairCorr |
| 0.82 | ANIP | ANI Pharmaceuticals Financial Report 13th of May 2024 | PairCorr |
| 0.81 | MRUS | Merus BV Financial Report 2nd of May 2024 | PairCorr |
| 0.8 | PAHC | Phibro Animal Health Financial Report 1st of May 2024 | PairCorr |
The ability to find closely correlated positions to Alnylam Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Alnylam Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Alnylam Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Alnylam Pharmaceuticals to buy it.
The correlation of Alnylam Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Alnylam Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Alnylam Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Alnylam Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Alnylam Pharmaceuticals Piotroski F Score and Alnylam Pharmaceuticals Altman Z Score analysis. For more information on how to buy Alnylam Stock please use our How to Invest in Alnylam Pharmaceuticals guide.You can also try the Commodity Channel module to use Commodity Channel Index to analyze current equity momentum.
Complementary Tools for Alnylam Stock analysis
When running Alnylam Pharmaceuticals' price analysis, check to measure Alnylam Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Alnylam Pharmaceuticals is operating at the current time. Most of Alnylam Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Alnylam Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Alnylam Pharmaceuticals' price. Additionally, you may evaluate how the addition of Alnylam Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences |
Is Alnylam Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Alnylam Pharmaceuticals. If investors know Alnylam will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Alnylam Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.52) | Revenue Per Share 14.637 | Quarterly Revenue Growth 0.312 | Return On Assets (0.05) | Return On Equity (15.01) |
The market value of Alnylam Pharmaceuticals is measured differently than its book value, which is the value of Alnylam that is recorded on the company's balance sheet. Investors also form their own opinion of Alnylam Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Alnylam Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Alnylam Pharmaceuticals' market value can be influenced by many factors that don't directly affect Alnylam Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Alnylam Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Alnylam Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Alnylam Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.